Related Experiment Videos
Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma
Raymond Alexanian1, Donna Weber, Athanasios Anagnostopoulos
1The University of Texas M.D. Anderson Cancer Center, Box 429, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Seminars in Hematology
|March 16, 2004
Summary
Thalidomide combined with dexamethasone shows effectiveness in treating relapsed or resistant multiple myeloma. This combination therapy offers a safe and viable treatment option, improving remission rates and survival for patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma is a hematologic malignancy.
- Thalidomide and high-dose dexamethasone are known active agents.
- Standard treatments may fail for relapsed or resistant disease.
Purpose of the Study:
- To evaluate the efficacy and safety of thalidomide alone and in combination with dexamethasone.
- To assess treatment outcomes in patients with relapsed or resistant multiple myeloma.
- To determine the effectiveness of this combination as consolidation therapy.
Main Methods:
- Retrospective summary of patient experiences.
- Treatment with thalidomide alone or thalidomide/dexamethasone.
- Response criteria included reduction in serum myeloma protein and Bence Jones protein.
Main Results:
- 47% remission rate in relapsed/resistant patients treated with thalidomide/dexamethasone.
- Significant survival prolongation for responsive patients.
- 52% achieved >90% myeloma protein reduction when used as consolidation in naive patients.
Conclusions:
- Thalidomide/dexamethasone is a safe and effective combination for resistant/relapsing multiple myeloma.
- It serves as a valuable consolidation therapy after intensive treatment.
- Side effects were manageable and often preventable.